Literature DB >> 1248156

Intermittent treatment with human growth hormone (GH) in isolated GH deficiency and in multiple pituitary hormone deficiencies.

A Pertzelan, R Kauli, S Assa, D Greenberg, Z Laron.   

Abstract

The results of intermittent GH treatment of 3-7 1/2 years duration in seven patients with isolated GH deficiency (IGHD) and five patients with multiple pituitary hormone deficiencies (MPHD) are presented. This therapeutic schedule was found to be comparably effective to those using a continuous-administration schedule. In contradistinction to the findings obtained with the latter, there was no progressive decline in growth velocity. The patients with IGHD were found to respond better than the patients with MPHD both in the first course as well as in consequent courses. In the intervals between courses, the growth velocity was less than in the pretreatment period in both groups. It is concluded that optimal results can be obtained by instituting an initial course of continuous treatment of 1 year's duration for the IGHD patients and of 2 years' duration for the MPHD patients, followed by an intermittent therapeutic schedule. This regime not only leads to the same growth achievement obtained with long-term continuous administration of GH but allows conservation of supplies of this very scarce hormone.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 1248156

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  3 in total

1.  Therapeutic use of human growth hormone.

Authors:  A S Mason
Journal:  J Clin Pathol Suppl (Assoc Clin Pathol)       Date:  1976

Review 2.  Optimum use of growth hormone in children.

Authors:  Z Laron; O Butenandt
Journal:  Drugs       Date:  1991-07       Impact factor: 9.546

3.  Intermittent injections of osteocalcin improve glucose metabolism and prevent type 2 diabetes in mice.

Authors:  Mathieu Ferron; Marc D McKee; Robert L Levine; Patricia Ducy; Gérard Karsenty
Journal:  Bone       Date:  2011-04-29       Impact factor: 4.398

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.